Roivant Sciences (RIVX) Shares Up 17% on Positive Phase 2 Data for Brepocitinib

Roivant Sciences (RIVX) surged 17% in premarket trading on February 07, 2026, following the announcement of positive results from its Phase 2 study of brepocitinib, a dual PI3K/mTOR inhibitor, in combination with pembrolizumab for treating advanced melanoma. The study met its primary endpoint, showing a statistically significant improvement in progression-free survival. The company reported that 56% of patients treated with brepocitinib plus pembrolizumab achieved disease control at 12 weeks, compared to 35% with pembrolizumab alone. Roivant plans to file a New Drug Application in the first half of 2026 and is evaluating additional combination regimens.